Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1029.09% is in line with its 1-year average of -1051.32%, around the middle of its 1-year range (-1193.92%–-913.13%).
0.61% above its 12-month average of -1035.40%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1193.92%.
EBITDA MARGIN
-1029.09%
EBITDA MARGIN AVG TTM
-1035.40%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.61%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
BioAge Labs Inc.
Market Cap
$232.62M
EBITDA Margin
-1029.09%
TTM Avg
-1035.40%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$233.59M
EBITDA Margin
-43.93%
TTM Avg
-56.69%
3Y Avg
-115.93%
5Y Avg
-139.79%
Market Cap
$230.29M
EBITDA Margin
-25.05%
TTM Avg
-32.88%
3Y Avg
-63.97%
5Y Avg
-61.52%
Market Cap
$237.84M
EBITDA Margin
10.49%
TTM Avg
1.20%
3Y Avg
-4.19%
5Y Avg
-40.04%
Market Cap
$238.48M
EBITDA Margin
25.65%
TTM Avg
38.25%
3Y Avg
43.91%
5Y Avg
51.79%
Market Cap
$239.07M
EBITDA Margin
-163095.33%
TTM Avg
-97357.05%
3Y Avg
-88166.59%
5Y Avg
-88166.59%
Market Cap
$226.20M
EBITDA Margin
-252.79%
TTM Avg
-276.80%
3Y Avg
-348.01%
5Y Avg
-340.44%
Market Cap
$241.02M
EBITDA Margin
-100.05%
TTM Avg
-392.29%
3Y Avg
-392.29%
5Y Avg
-392.29%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioAge Labs Inc. (BIOA) | $232.62M | -1029.09% | -1035.40% | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $233.59M | -43.93% | -56.69% | -115.93% | -139.79% |
| Biodesix, Inc. (BDSX)vs › | $230.29M | -25.05% | -32.88% | -63.97% | -61.52% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $237.84M | 10.49% | 1.20% | -4.19% | -40.04% |
| SIGA Technologies, Inc. (SIGA)vs › | $238.48M | 25.65% | 38.25% | 43.91% | 51.79% |
| High Tide Inc. (HITI)vs › | $238.91M | 1.66% | 3.74% | -1.53% | 0.81% |
| InflaRx N.V. (IFRX)vs › | $239.07M | -163095.33% | -97357.05% | -88166.59% | -88166.59% |
| Profound Medical Corp. (PROF)vs › | $226.20M | -252.79% | -276.80% | -348.01% | -340.44% |
| Invivyd, Inc. (IVVD)vs › | $241.02M | -100.05% | -392.29% | -392.29% | -392.29% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $241.80M | N/A | N/A | N/A | N/A |
Gross Margin
99.4%
EBITDA Margin
-1029.1%
Operating Margin
-1026.3%
Net Margin
-912.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1193.92% |
| 2026-03-31 | -913.13% |
| 2025-12-31 | -921.18% |
| 2025-09-30 | -1124.20% |
| 2025-06-30 | -1024.59% |
| 2025-03-31 | -1130.88% |
